AREV Life Sciences Global Corp
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- AREV Life Sciences Global Corp. operates as an early-stage life science discovery company focused on extracting and producing functional compounds and ingredients for nutraceuticals, clinical nutrition, and therapeutic applications; it serves natural health, medical, functional food, sport nutrition, and bio-ceutical markets through proprietary extraction systems and formulations. Core products include pipeline offerings such as SUS-TAINN, a ready-to-use therapeutic food for severe acute malnutrition, and RES-TORE, an organic plant-based nutrition supplement for enhanced caloric intake and micronutrients; branded nutraceuticals under BARE and Wright & Well labels encompassing cannabidiol-infused items like Canna-Mulsion, NaturVax anti-viral supplements, NaturRelax sleep aids, NaturRelief pain relief, CBD skincare, medicinal oils, and edibles; and ingredients derived from edible oils, moringa, hops, cannabis sativa, sea cucumber, ginseng, functional fungi, plus flash-frozen active compounds, oils, and oleoresins for food and consumer products. The company, founded prior to its 2021 name change from AREV NanoTec Brands Inc., maintains headquarters in Coquitlam, British Columbia, Canada, with a U.S. subsidiary established in Rochester, New York, in 2021 to expand biotechnology operations and access regional talent; it targets global markets via toll processing, licensing to licensed producers, and distribution in traditional and online channels. Recent developments feature strategic U.S. expansion through the wholly-owned AREV Life Sciences Inc. subsidiary in 2021, executive appointments including a chief operating officer and preclinical partnerships with TransBIOTech, alongside ongoing advancements in phytomedicinal antivirals, human nutrition therapeutics for chronic comorbidities, and collaborations with institutions like the Richardson Centre for Functional Foods and Nutraceuticals.
AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB
AREV Announces Brian Cameron as Chief Financial Officer
AREV Signs Definitive Collaborative Development Agreement with Voynich Biosciences and Invites Richard van Breemen PhD to SAB
Data Presented at the 11th IAS Conference on HIV Science Supports AREV's Development of SUS-TAINN™, a Ready-to-Use Therapeutic Food to Treat Global Malnutrition and Starvation
AREV Annual and Special General Meeting Results
AREV Expands Operations to Rochester New York Establishing Wholly Owned U.S. Subsidiary, AREV Life Sciences, Inc.
AREV Completes Land Survey and Soil Analysis for Cultivation of Mushrooms and Moringa and Prepares for Mass Production of Plant-Based Proteins For Use in Its Ready-To-Use Therapeutic Foods
AREV CEO Michael Withrow Buys 900,000 Shares of Company Stock
AREV Engages Dr. Harold C. Smith to Join Scientific Advisory Board
AREV Life Sciences Expands its Extraction Results to Clinical Characterization of Compounds, Development of Advanced-Stage Therapeutic Foods and Discovery of Plant-Based Drugs
AREV Nanotec Board of Directors Welcomes Kevin Phelps